Literature DB >> 26205745

[Unclear retinopathy after intravitreal injection of ocriplasmin].

S Abraham1, K Wand2, S Stumpfe2, N Feucht2, C P Lohmann2, M Maier2.   

Abstract

CASE REPORT: This article reports the case of a 50-year-old female patient who presented with reduced visual acuity of 0.8 p and metamorphopsia of the left eye caused by focal vitreomacular traction and who was treated with intravitreal Jetrea® (ocriplasmin). After injection the patient suffered from progressive nyctalopia and visual field defects. Electroretinography (ERG) showed decreased amplitudes and optical coherence tomography (OCT) showed decreased reflectivity in the ellipsoid layer that persisted for 2 months after treatment.
CONCLUSION: Before injection of Jetrea® a detailed clarification of such potential side effects is necessary to increase patient compliance in the follow-up.

Entities:  

Keywords:  Optical coherence tomography; Retina; Visual field; Visual loss; Vitreomacular traction

Mesh：

Substances：

Year:  2016        PMID： 26205745     DOI： 10.1007/s00347-015-0080-0

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN： 0941-293X            Impact factor:   1.059


  6 in total

1.  Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes.

Authors:  Peter Stalmans; Matthew S Benz; Arnd Gandorfer; Anselm Kampik; Aniz Girach; Stephen Pakola; Julia A Haller
Journal:  N Engl J Med       Date:  2012-08-16       Impact factor: 91.245

2.  Correlation of transient vision loss with outer retinal disruption following intravitreal ocriplasmin.

Authors:  K B Freund; S A Shah; V P Shah
Journal:  Eye (Lond)       Date:  2013-05-03       Impact factor: 3.775

3.  Treatment outcomes and spectral-domain optical coherence tomography findings of eyes with symptomatic vitreomacular adhesion treated with intravitreal ocriplasmin.

Authors:  David J Warrow; Michael M Lai; Auvni Patel; Joseph Raevis; Daniel M Berinstein
Journal:  Am J Ophthalmol       Date:  2014-09-16       Impact factor: 5.258

4.  Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome.

Authors:  Rishi P Singh; Ang Li; Rumneek Bedi; Sunil Srivastava; Jonathan E Sears; Justis P Ehlers; Andrew P Schachat; Peter K Kaiser
Journal:  Br J Ophthalmol       Date:  2013-12-19       Impact factor: 4.638

5.  Acute panretinal structural and functional abnormalities after intravitreous ocriplasmin injection.

Authors:  Abigail T Fahim; Naheed W Khan; Mark W Johnson
Journal:  JAMA Ophthalmol       Date:  2014-04-01       Impact factor: 7.389

6.  Vision loss after intravitreal ocriplasmin: correlation of spectral-domain optical coherence tomography and electroretinography.

Authors:  Michael D Tibbetts; Elias Reichel; Andre J Witkin
Journal:  JAMA Ophthalmol       Date:  2014-04-01       Impact factor: 7.389
  6 in total
  3 in total

1.  [Ocriplasmin as a treatment option for symptomatic vitreomacular traction with and without macular hole. First clinical experiences].

Authors:  M Maier; S Abraham; C Frank; N Feucht; C P Lohmann
Journal:  Ophthalmologe       Date:  2015-12       Impact factor: 1.059

2.  [Pharmaological vitreolysis with ocriplasmin as a treatment option for symptomatic focal vitreomacular traction with or without macular holes (≤400 μm) compared to tranconjunctival vitrectomy].

Authors:  M Maier; S Abraham; C Frank; C P Lohmann; N Feucht
Journal:  Ophthalmologe       Date:  2017-02       Impact factor: 1.059

Review 3.  Ocriplasmin: who is the best candidate?

Authors:  Claudia M Prospero Ponce; William Stevenson; Rachel Gelman; Daniel R Agarwal; John B Christoforidis
Journal:  Clin Ophthalmol       Date:  2016-03-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.